In 2013, not quite a year after the Food and Drug Administration approved the drug Truvada for HIV prevention, a coalition of 50 experts in HIV and women’s health called on U.S. public health agencies to promote the pill and its approach, called pre-exposure prophylaxis, or PrEP, explicitly to women.
Not much happened. Read More
